Xero share price slides after Trump tariff threat hits tech — ASX:XRO sinks to 12‑month low
19 January 2026
2 mins read

Xero share price slides after Trump tariff threat hits tech — ASX:XRO sinks to 12‑month low

SYDNEY, Jan 19, 2026, 16:51 AEDT — The market has closed.

  • Xero slipped 2.6% to A$100.89, hitting a 12-month low of A$98.23 earlier in the session
  • Australia’s benchmark index fell 0.33%, weighed down largely by losses in IT
  • Traders are eyeing tariff updates closely, while also monitoring if Xero can stay above the A$100 mark heading into Tuesday

Cloud accounting software provider Xero Ltd (XRO.AX) slipped 2.6% to close at A$100.89 on Monday, hitting a 12-month low of A$98.23 earlier in the session. The stock started the day at A$103.25 and peaked at A$103.35. Since January, shares have dropped roughly 10%, with around 889,000 shares traded, according to market data. 1

The drop followed investor retreat from risk after U.S. President Donald Trump threatened tariffs on several European countries over Greenland, raising fears of a trade war. “Markets are pricing in increased political risk premia on the U.S. dollar,” said Khoon Goh, head of Asia research at ANZ in Singapore. 2

Shocks like that usually hit “long-duration” growth stocks hard — these are shares valued based on profits far in the future. When uncertainty spikes, investors quickly reassess how much those distant earnings are really worth now.

In Sydney, the S&P/ASX 200 dropped 0.33%, weighed down by falls in IT, telecom services, and consumer discretionary sectors, according to Investing.com. 3

Australian tech stocks took a hit, with WiseTech Global falling 4.4% to close at A$64.07, hitting a low of A$63.25 during the session. 4

Xero faces a supply issue after an ASX filing on Jan. 15 revealed that 1,255,936 securities tied to its Melio acquisition were “released from voluntary escrow restrictions” and are now freely tradable. 5

A voluntary escrow means shares are locked up and can’t be sold for a specific time. Once those restrictions expire, the market often faces a sudden influx of shares, regardless of any change in the company’s fundamentals.

The Melio deal remains a key part of the debate around the stock. Last year, Xero agreed to acquire U.S.-Israeli payments firm Melio for up to $3 billion as it aimed to expand into North America, where it generated roughly 7% of its sales, Reuters reported. “There is much to like in terms of bulking up U.S. exposure,” said RBC Capital Markets analyst Garry Sherriff at the time. 6

The acquisition brings payments capabilities into Xero’s accounting software, but it raises concerns about integration challenges and added costs. Competition remains fierce, with global players like Intuit and Sage battling for the small-business market.

The next move could swing either way. Should tariff threats escalate and volatility climb, high-multiple software stocks might sell off despite solid company performance; a sustained drop below A$100 could trigger a wave of short-term selling.

Before Tuesday’s open, eyes will be on Xero to see if it can hold firm after dipping below A$100. Traders will also track new tariff developments that could weigh on global tech stocks. Xero’s next key date is its FY26 full-year results, set for May 14, as noted in an ASX release. 7

Stock Market Today

Amgen stock price hits 52-week high after Friday rally — what to watch into Monday

Amgen stock price hits 52-week high after Friday rally — what to watch into Monday

7 February 2026
New York, Feb 7, 2026, 17:15 EST — Market closed. Amgen Inc shares closed up 4.5% on Friday at $384.32, setting a new 52-week high as a three-day advance carried into the weekend. 1 The move matters because the stock is running into two forces that can pull in opposite directions: payer pushback on older blockbuster drugs, and renewed attention on Amgen’s longer-dated growth bets. CVS Health said its Caremark pharmacy benefit manager will remove Amgen’s osteoporosis drug Prolia — and Eli Lilly’s Forteo — from some preferred drug lists starting April 1, swapping in lower-cost biosimilars and generics. 2
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
GE Vernova stock closes up nearly 6% — what to watch before Monday’s trade

GE Vernova stock closes up nearly 6% — what to watch before Monday’s trade

7 February 2026
GE Vernova shares jumped 5.6% to $779.35 Friday as Wall Street rallied and the company reported 1.1 GW of U.S. wind repower orders for 2025. The company also closed its $5.3 billion purchase of the remaining Prolec GE stake and completed a $2.6 billion senior notes offering. Investors await next week’s U.S. jobs and inflation data.
CSL share price rises after RBC upgrade, with Feb results now the next test
Previous Story

CSL share price rises after RBC upgrade, with Feb results now the next test

CBA shares slide as ASX snaps winning run — what to watch before earnings
Next Story

CBA shares slide as ASX snaps winning run — what to watch before earnings

Go toTop